Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Regorafenib
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Colorectal Cancer
Fabricant:
Bayer Inc.
Brand Name:
Stivarga (CRC)
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0026-000
Strength:
40 mg tablets
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
The treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy
Review Status:
Complete
Date NOC Issued:
Sponsor:
Bayer Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Ne pas rembourser
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016